Treatment options for tic disorders

References

• Kurlan R, McDermott MP, Deeley C, et al. Prevalence of tics in schoolchildren and association with placement in special education. Neurology. 2001;23:1383–1388.
   Google Scholar
• Gulisano M, Calì P, Palermo F, et al. Premonitory urges in patients with Gilles de la Tourette syndrome: an Italian translation and a 7-year follow-up. J Child Adolesc Psychopharmacol. 2015;25:810–816.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The Fifth Edition of the diagnostic and statistical manual of mental disorders (DSM-5). Washington D.C; 2013. p. 947.
   Google Scholar
• Augustine F, Singer HS. Merging the pathophysiology and pharmacotherapy of tics. Tremor Other Hyperkinet Mov (N Y). 2019;8:595.
   PubMedGoogle Scholar
• Robertson MM. A personal 35 year perspective on Gilles de la Tourette syndrome: assessment, investigations, and management. Lancet Psychiatry. 2015;2:291.
   Web of Science ®Google Scholar
• Robertson MM, Eapen V, Singer HS, et al. Gilles de la Tourette syndrome. Nat Rev Dis Primers. 2017;3:16097.
   PubMed Web of Science ®Google Scholar
• Hirschtritt ME, Lee PC, Pauls DL, et al. Tourette Syndrome Association International Consortium for Genetics. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015;72:325–333.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Gulisano M, Martino D, et al. Gilles de la Tourette syndrome, depression, depressive illness, and correlates in a child and adolescent population. J Child Adolesc Psychopharmacol. 2017;27:243–249.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Gulisano M, Domini CN, et al. The relationship between autism spectrum disorder and tourette syndrome in childhood: an overview of shared characteristics. J Ped Neurol. 2017;15:3.
   Web of Science ®Google Scholar
• Müller-Vahl KR, Sambrani T, Jakubovski E. Tic disorders revisited: introduction of the term “tic spectrum disorders”. Eur Child Adolesc Psychiatry. 2019;28:1129–1135.
   Web of Science ®Google Scholar
• Pittenger C. The neurobiology of tic disorders and obsessive-compulsive disorder In: Charney DS, Nestler EJ, Sklar P, et al., editors. Charney and Nestler’s neurobiology of mental illness 5th ed. Oxford University Press; 2017.
   Google Scholar
• Worbe Y, Lehericy S, Hartmann A. Neuroimaging of tic genesis: present status and future perspectives. Mov Disord. 2015;30:1179–1183.
   PubMed Web of Science ®Google Scholar
• Worbe Y, Marrakchi-Kacem L, Lecomte S, et al. Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome. Brain. 2015;138:472–482.
   PubMed Web of Science ®Google Scholar
• Qi Y, Zheng Y, Li Z, et al. Genetic Studies of Tic Disorders and Tourette syndrome. Methods Mol Biol. 2019;2011:547–571.
   PubMedGoogle Scholar
• Brainstorm Consortium. Analysis of shared heritability in common disorders of the brain. Science. 2018;22:360.
   Google Scholar
• Yu D, Sul JH, Tsetsos F. et al. Interrogating the genetic determinants of Tourette’s syndrome and other tic disorders through genome-wide association studies. Am J Psychiatry. 2019;176:217–227.
   PubMed Web of Science ®Google Scholar
• Roessner V, Plessen KJ, Rothenberger A. et al. European clinical guidelines for Tourette syndrome and other tic disorders Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173–196.
   PubMed Web of Science ®Google Scholar
• Deckersbach T, Chou T, Britton JC, et al. Neural correlates of behavior therapy for Tourette’s disorder. Psychiatry Res. 2014;30(224):269–274.
   Google Scholar
• Rizzo R, Pellico A, Silvestri PR, et al. A randomized controlled trial comparing behavioral, educational, and pharmacological treatments in youths with chronic tic disorder or Tourette syndrome. Front Psychiatry. 2018;9:100.
   PubMed Web of Science ®Google Scholar
• Farag M, Stern JS, Simmons H, et al. Serial pharmacological prescribing practices for tic management in Tourette syndrome. Hum Psychopharmacol. 2015;30:435–441.
   PubMed Web of Science ®Google Scholar
• Hollis C, Pennant M, Cuenca J, et al. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess. 2016;20:1–450.
   PubMed Web of Science ®Google Scholar
• Murphy TK, Lewin AB, Storch EA, et al. American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry. 2013;52:1341–1359.
   PubMed Web of Science ®Google Scholar
• Mogwitz S, Buse J, Ehrlich S, et al. Clinical pharmacology of dopamine-modulating agents in Tourette’s syndrome. Int Rev Neurobiol. 2013;112:281–349.
   PubMed Web of Science ®Google Scholar
• Bloch M, State M, Pittenger C. Recent advances in Tourette syndrome. Curr Opin Neurol. 2011;24:119–125.
   PubMed Web of Science ®Google Scholar
• Roth J. The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies. Parkinsonism Relat Disord. 2018;46:75–79.
   PubMed Web of Science ®Google Scholar
• AIFA, Agenzia Italiana per il farmaco. “Pimozide data sheet” addeddum I, June 2016
   Google Scholar
• Gulisano M, Calì PV, Cavanna AE, et al. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32:1213–1217.
   PubMed Web of Science ®Google Scholar
• Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS Drugs. 2018;32:33–45.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Marras C. Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev. 2009;15:CD006996.
   Google Scholar
• Rizzo R, Eddy CM, Calí P, et al. Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome. Pediatr Neurol. 2012;47:419–422.
   PubMed Web of Science ®Google Scholar
• Rafaniello C, Pozzi M, Pisano S, et al. Second generation antipsychotics in ‘real-life’ paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Exp Opin Drug Saf. 2016;15:1–8.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Cattaneo D, Baldelli S, et al. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol. 2016;72:285–293.
   PubMed Web of Science ®Google Scholar
• Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;62:50–56.
   PubMed Web of Science ®Google Scholar
• Gilbert DL, Batterson JR, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43:206–214.
   PubMed Web of Science ®Google Scholar
• Dion Y, Annable L, Sandor P, et al. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22:31–39.
   PubMed Web of Science ®Google Scholar
• Gaffney G, Perry P, Lund B, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s disorder. J Am Acad Child Adolesc Psychiatry. 2002;41:330–336.
   PubMed Web of Science ®Google Scholar
• Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130–1135.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:596–603.
   PubMed Web of Science ®Google Scholar
• Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013;74:772–780.
   PubMed Web of Science ®Google Scholar
• Sallee F, Kohegyi E, Zhao J. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27:771–781.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39:292–299.
   PubMed Web of Science ®Google Scholar
• Whittington C, Pennant M, Kendall T. et al. Practitioner review: treatments for Tourette syndrome in children and young people - a systematic review. J Child Psychol Psychiatry. 2016;57:988–1004.
   PubMed Web of Science ®Google Scholar
• Weisman H, Qureshi IA, Leckman JF, et al. Systematic review: pharmacological treatment of tic disorders – efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev. 2013;37:1162–1171.
   PubMed Web of Science ®Google Scholar
• McCracken JT, Suddath R, Chang S, et al. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol. 2008;18:501–518.
   PubMed Web of Science ®Google Scholar
• Budman CL, Gayer A, Lesser M, et al. An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry. 2001;62:290–294.
   PubMed Web of Science ®Google Scholar
• Stamenkovic M, Schindler SD, Aschauer HN, et al. Effective open-label treatment of Tourette’s disorder with olanzapine. Int Clin Psychopharmacol. 2000;15:23–28.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998;8:107–113.
   PubMed Web of Science ®Google Scholar
• Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette’s syndrome–a pilot study. J Child Adolesc Psychopharmacol. 2004;14:255–266.
   PubMed Web of Science ®Google Scholar
• Onofrj M, Paci C, D’Andreamatteo G, et al. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol. 2000;247:443–446.
   PubMed Web of Science ®Google Scholar
• Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:600–620.
   PubMed Web of Science ®Google Scholar
• de Jonge JL, Cath DC, van Balkom AJ. Quetiapine in patients with Tourette’s disorder: an open-label, flexible-dose study. J Clin Psychiatry. 2007;68:1148–1150.
   PubMed Web of Science ®Google Scholar
• Montejo ÁL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25–34.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry. 2012;57:133–143.
   PubMed Web of Science ®Google Scholar
• Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995;95:74–81.
   PubMed Web of Science ®Google Scholar
• Leckman JF, Hardin MT, Riddle MA, et al. Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry. 1991;48:324–328.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Wilson RS, et al. Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol. 1987;21:307–310.
   PubMed Web of Science ®Google Scholar
• Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;26:527–536.
   Google Scholar
• Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol. 2009;40:420–425.
   PubMed Web of Science ®Google Scholar
• Du YS, Li HF, Vance A, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry. 2008;42:807–813.
   PubMed Web of Science ®Google Scholar
• Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disordersand attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067–1074.
   PubMed Web of Science ®Google Scholar
• Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol. 2002;25:325–332.
   PubMed Web of Science ®Google Scholar
• Murphy TK, Fernandez TV, Coffey BJ, et al. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol. 2017;27:762–770.
   PubMed Web of Science ®Google Scholar
• Awaad Y. Tics in Tourette syndrome: new treatment options. J Child Neurol. 1999;14:316–319.
   PubMed Web of Science ®Google Scholar
• Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology. 2001;13:599–604.
   Google Scholar
• Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81:70–73.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord. 2011;26:1149–1156.
   PubMed Web of Science ®Google Scholar
• Porta M, Sassi M, Cavallazzi M, et al. Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig. 2008;28:443–459.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17:2461–2470.
   PubMed Web of Science ®Google Scholar
• Hazekamp A, Ware MA, Muller-Vahl KR, et al. The medicinal use of cannabis and cannabinoids–an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199–210.
   PubMed Web of Science ®Google Scholar
• Muller-Vahl KR. Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 2013;27:119–124.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313:2456–2473.
   PubMed Web of Science ®Google Scholar
• Gilbert DL, Budman CL, Singer HS, et al. A D1 receptor antagonist, Ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014;37:26–30.
   PubMed Web of Science ®Google Scholar
• Gilbert D, Murphy T, Jankovic J, et al. A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome. Mov Disord. 2018;33:1272–1280.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in Tics associated with Tourette Syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6:422.
   PubMed Web of Science ®Google Scholar
• Kim ES. Valbenazine: first Global Approval. Drugs. 2017;77:1123–1129.
   PubMed Web of Science ®Google Scholar
• Karagiannidis I, Dehning S, Sandor P, et al. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet. 2013;50:760–764.
   PubMed Web of Science ®Google Scholar
• Kakusa B, Saluja S, Tate WJ, et al. Robust clinical benefit of multi-target deep brain stimulation for treatment of Gilles de la Tourette syndrome and its comorbidities. Brain Stimul. 2019;pii:S1935-861X(19)30079–8.
   Google Scholar
• Macerollo A, Martino D, Cavanna AE, et al. Refractoriness to pharmacological treatment for tics: A multicentre European audit. J Neurol Sci. 2016;366:136–138.
   PubMed Web of Science ®Google Scholar
• Kious BM, Jimenez-Shahed J, Shprecher DR. Treatment-refractory Tourette Syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:227–236.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Gulisano M. Treatment resistance in Tourette syndrome. In: Yong-Ku K, editor. Treatment resistance in psychiatry: risk factors, biology and management. Springer Nature; 2019. 237–252.
   Google Scholar
• Rizzo R, Gulisano M, Pellico A, et al. Tourette syndrome and comorbid conditions: a spectrum of different severities and complexities. J Child Neurol. 2014;29:1383–1389.
   PubMed Web of Science ®Google Scholar
• Kim DD, Barr AM, Chung Y, et al. Antipsychotic-associated symptoms of Tourette syndrome: a systematic review. CNS Drugs. 2018;32:917–938.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Gulisano M, Calì PV, et al. Long term clinical course of Tourette syndrome. Brain Dev. 2012;34:667–673.
   PubMed Web of Science ®Google Scholar